Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Phase II StudyÂ of Sequential Pembrolizumab (PEM)Â FollowedÂ By AVD for Frontline TreatmentÂ of Classical Hodgkin Lymphoma (CHL): Quantifying Response FollowingÂ PEM MonotherapyÂ with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

Hatice Savas, MD, Pamela Allen, MDMSc, Andrew M. Evens, DO, MSc, Barbara Pro, MD, Gary Dillehay, MD, Alfred Rademaker, PhD, Brett Alan Palmer, BS, Ranjana Advani, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2018) 132 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2018-99-113836

Published: 2018

Journal Articles

A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update

Jeanette Lundin, MD PhD, Steven T. Rosen, MD, Anders Österborg, MDPhD, Olga Frankfurt, MD, Jane N. Winter, MD, Alfred Rademaker, Jennifer Kreutzer, Elizabeth Bacon, Sonja Sönnert-Husa, Shuo Ma, MD PhD

Blood (2015) 126 (23): 1734.

https://doi.org/10.1182/blood.V126.23.1734.1734

Published: 2015

Journal Articles

Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts

Blood (2011) 118 (21): 942.

https://doi.org/10.1182/blood.V118.21.942.942

Published: 2011

Journal Articles

Does Methotrexate Affect Transplant Outcomes? Transplant Related Mortality (TRM), Engraftment, Graft Vs. Host Disease (GvHD), Overall Survival (OS) and Event Free Survival (EFS) in 142 Consecutive Pediatric Cord Blood Transplants (CBT) At Children's Memorial Hospital (CMH)

Morris Kletzel, MD, Mebhoob Merchant, Nazneen Merchant, CRA, Alfred Rademaker, STATISTICIAN PHD, Reggie Duerst, MD, Sonali Chaudhury, M.D., Jennifer Schneiderman, MD, MS, William T. Tse, MD, PhD

Blood (2011) 118 (21): 3028.

https://doi.org/10.1182/blood.V118.21.3028.3028

Published: 2011

Journal Articles

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Rupali Roy, M.D., Andrew M Evens, DO, MSc, David P. Patton, B.S., Annette Larsen, B.S., R.N., Alfred Rademaker, Ph.D., Jeffrey Cilley, M.D., Stewart Spies, M.D., Daina Variakojis, M.D., Leo I Gordon, M.D., Jane N. Winter, M.D.

Blood (2010) 116 (21): 1749.

https://doi.org/10.1182/blood.V116.21.1749.1749

Published: 2010

Journal Articles

Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study

David A. Jacobsohn, Andrew L. Gilman, Alfred Rademaker, Brittan Browning, Michael Grimley, Leslie Lehmann, Eneida R. Nemecek, Kimberly Thormann, Kirk R. Schultz, Georgia B. Vogelsang

Blood (2009) 114 (20): 4354–4360.

https://doi.org/10.1182/blood-2009-05-224840

Published: 2009

Includes: Supplemental data

Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90 YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

Jane N. Winter, MD, David Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, B.S., William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Andrew Evens, D.O., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.

Blood (2006) 108 (11): 330.

https://doi.org/10.1182/blood.V108.11.330.330

Published: 2006

Journal Articles

Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

Christiane Querfeld, MD, Steven T. Rosen, MD, Joan Guitart, MD, Brenda Martone, RN, MSN, Alfred Rademaker, PhD, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 2732.

https://doi.org/10.1182/blood.V108.11.2732.2732

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation (AuSCT) with Total Lymphoid Irradiation (TLI) and High-Dose Chemotherapy (CT) Results in High Survival Rates for “Poor-Prognosis” Relapsed/Refractory (R/R) Hodgkin’s Disease (HD): Multivariate Analysis of Outcome Shows Marked Benefit for TLI in a Prospective Phase I/II Trial.

Andrew M. Evens, DO, MS, Alfred Rademaker, PhD, Bharat B. Mittal, MD, Jessica K. Altman, MD, David Patton, BS, Lynne Kaminer, MD, Seema Singhal, MD, Daina Variakojis, MD, Stephanie Williams, MD, Martin S. Tallman, MD, Jayesh N. Mehta, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2005) 106 (11): 2080.

https://doi.org/10.1182/blood.V106.11.2080.2080

Published: 2005

Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Jane N. Winter, M.D., David J. Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie F. Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.

Blood (2004) 104 (11): 1162.

https://doi.org/10.1182/blood.V104.11.1162.1162

Published: 2004

NARROW

A Phase II StudyÂ of Sequential Pembrolizumab (PEM)Â FollowedÂ By AVD for Frontline TreatmentÂ of Classical Hodgkin Lymphoma (CHL): Quantifying Response FollowingÂ PEM MonotherapyÂ with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update

Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts

Does Methotrexate Affect Transplant Outcomes? Transplant Related Mortality (TRM), Engraftment, Graft Vs. Host Disease (GvHD), Overall Survival (OS) and Event Free Survival (EFS) in 142 Consecutive Pediatric Cord Blood Transplants (CBT) At Children's Memorial Hospital (CMH)

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study

90 Y Ibritumomab Tiuxetan (Zevalin®; 90 YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only